Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OTID: GLP1RA and SGLT2i in T1D with CKD
NCT05390307Completed
- Sponsor
- Dasman Diabetes Institute
- Start
- Apr 2023
- Primary completion
- Jan 2024
- Modality
- Peptides, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of liraglutide, semaglutide and dapagliflozin in type 1 diabetes mellitus (T1D), chronic kidney disease (CKD) and obesity (5 arms), sponsored by Dasman Diabetes Institute. Primary endpoint: Weight at 26 weeks. Started Apr 2023; status: completed.
02
Drugs
03
Conditions
type 1 diabetes mellitus (T1D)chronic kidney disease (CKD)obesity
Beyond the preview
Go deeper on NCT05390307.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05390307.